1. Home
  2. EXFY vs EQ Comparison

EXFY vs EQ Comparison

Compare EXFY & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.05

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.08

Market Cap

129.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
EQ
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
129.0M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
EXFY
EQ
Price
$1.05
$2.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$4.50
$8.00
AVG Volume (30 Days)
590.0K
370.4K
Earning Date
05-07-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,101,000.00
$41,095,000.00
Revenue This Year
$0.42
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$0.29
52 Week High
$3.06
$2.70

Technical Indicators

Market Signals
Indicator
EXFY
EQ
Relative Strength Index (RSI) 66.71 52.83
Support Level $0.77 $1.60
Resistance Level $1.54 $2.13
Average True Range (ATR) 0.06 0.21
MACD 0.03 0.00
Stochastic Oscillator 100.00 49.06

Price Performance

Historical Comparison
EXFY
EQ

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: